ITRMF · Iterum Therapeutics plc
$0.03
+0.01 (+34.78%)
At close · Jul 21
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“This condition raises substantial doubt about the Company's ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 14, 2025
Market Cap
$446
Shares
44.66M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.03
Day$0.03–0.03
52W close$0.01–0.87
Avg vol 30d39K
Short int1.7M · 3.9% float · 999+d
Short vol100%
Last earningsNov 14, 2025
DataAug 2022–Jul 2026
Filing10-Q · Nov 14
Raw chart and full-history price indicators begin at the captured split on Aug 18, 2022; bars on opposite sides are not compared.
Up next
filed Nov 14, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$26.96M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+128.5%
Year over year · more shares
Price change (1Y)
-96.4%
Trailing year
Short interest
3.9%
Latest settlement · 999+ days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.1 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−88%
below
Price vs 50-day avg
−33%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−25%
trailing
6-month return
−91%
trailing
YTD return
−91%
this year
Relative strength
−99%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-89% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
3.89% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Squeeze score
63
elevated · 0–100
Fundamentals
EPS growth
+57%
Y/Y
Free cash flow
$-26.8M
Balance sheet
$7.1M
net debt
Quant / Vol
risk profile
Volatility
382%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
44.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Nov 14, 2025
Net product sales of ORLYNVAH™
· 2026
$5M – $15M
Prior guidance
period ended
· from the Earnings Call filed Mar 12, 2021
R&D spending
· first half of 2021
$6M – $8M
SG&A expense
· first half of 2021
$9M – $11M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−88%
Bearish
Price vs 50-day avg
−33%
Bearish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Distributing
-89% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
3.89% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 3%
Range high $1
vs 200-day avg -88%
vs 50-day avg -33%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ITRMF
this stock
Iterum Therapeutics plc
|
$446 | -90.7% | — | — | 3.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.87B | +17.1% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$58.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
2
- % held
- 0.0%
- Net QoQ
- -1.4M sh
- Top holder
- BARCLAYS PLC
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Aug 18, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ITRMF | -6.1% | -25.5% | -91.5% | -37.9% | -90.8% |
| SPY | -0.5% | +0.5% | +7.6% | +0.2% | +9.7% |
| vs SPY | -5.6% | -26.0% | -99.1% | -38.1% | -100.5% |